Literature DB >> 20605778

Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases.

Oras Mistafa1, Aram Ghalali, Sandeep Kadekar, Johan Högberg, Ulla Stenius.   

Abstract

Akt is an important oncoprotein, and data suggest a critical role for nuclear Akt in cancer development. We have previously described a rapid (3-5 min) and P2X7-dependent depletion of nuclear phosphorylated Akt (pAkt) and effects on downstream targets, and here we studied mechanisms behind the pAkt depletion. We show that cholesterol-lowering drugs, statins, or extracellular ATP, induced a complex and coordinated response in insulin-stimulated A549 cells leading to depletion of nuclear pAkt. It involved protein/lipid phosphatases PTEN, pleckstrin homology domain leucine-rich repeat phosphatase (PHLPP1 and -2), protein phosphatase 2A (PP2A), and calcineurin. We employed immunocytology, immunoprecipitation, and proximity ligation assay techniques and show that PHLPP and calcineurin translocated to the nucleus and formed complexes with Akt within 3 min. Also PTEN translocated to the nucleus and then co-localized with pAkt close to the nuclear membrane. An inhibitor of the scaffolding immunophilin FK506-binding protein 51 (FKBP51) and calcineurin, FK506, prevented depletion of nuclear pAkt. Furthermore, okadaic acid, an inhibitor of PP2A, prevented the nuclear pAkt depletion. Chemical inhibition and siRNA indicated that PHLPP, PP2A, and PTEN were required for a robust depletion of nuclear pAkt, and in prostate cancer cells lacking PTEN, transfection of PTEN restored the statin-induced pAkt depletion. The activation of protein and lipid phosphatases was paralleled by a rapid proliferating cell nuclear antigen (PCNA) translocation to the nucleus, a PCNA-p21(cip1) complex formation, and cyclin D1 degradation. We conclude that these effects reflect a signaling pathway for rapid depletion of pAkt that may stop the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20605778      PMCID: PMC2934657          DOI: 10.1074/jbc.M110.117093

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors.

Authors:  M Andjelković; T Jakubowicz; P Cron; X F Ming; J W Han; B A Hemmings
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN.

Authors:  Xinjiang Wang; Lloyd C Trotman; Theresa Koppie; Andrea Alimonti; Zhenbang Chen; Zhonghua Gao; Junru Wang; Hediye Erdjument-Bromage; Paul Tempst; Carlos Cordon-Cardo; Pier Paolo Pandolfi; Xuejun Jiang
Journal:  Cell       Date:  2007-01-12       Impact factor: 41.582

3.  PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms.

Authors:  Daniel J Freeman; Andrew G Li; Gang Wei; Heng-Hong Li; Nathalie Kertesz; Ralf Lesche; Andrew D Whale; Hilda Martinez-Diaz; Nora Rozengurt; Robert D Cardiff; Xuan Liu; Hong Wu
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

4.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

5.  Statins induce mammalian target of rapamycin (mTOR)-mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs.

Authors:  Emilie Roudier; Oras Mistafa; Ulla Stenius
Journal:  Mol Cancer Ther       Date:  2006-11       Impact factor: 6.261

6.  FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt.

Authors:  Huadong Pei; Liang Li; Brooke L Fridley; Gregory D Jenkins; Krishna R Kalari; Wilma Lingle; Gloria Petersen; Zhenkun Lou; Liewei Wang
Journal:  Cancer Cell       Date:  2009-09-08       Impact factor: 31.743

7.  Cyclin D1 inhibits cell proliferation through binding to PCNA and cdk2.

Authors:  J Fukami-Kobayashi; Y Mitsui
Journal:  Exp Cell Res       Date:  1999-02-01       Impact factor: 3.905

8.  An analog of a dipeptide-like structure of FK506 increases glial cell line-derived neurotrophic factor expression through cAMP response element-binding protein activated by heat shock protein 90/Akt signaling pathway.

Authors:  Xiaobo Cen; Atsumi Nitta; Shin Ohya; Yinglan Zhao; Naoya Ozawa; Akihiro Mouri; Daisuke Ibi; Li Wang; Makiko Suzuki; Kuniaki Saito; Yasutomo Ito; Tetsuya Kawagoe; Yukihiro Noda; Yoshihisa Ito; Shoei Furukawa; Toshitaka Nabeshima
Journal:  J Neurosci       Date:  2006-03-22       Impact factor: 6.167

9.  The tumour suppressor PTEN mediates a negative regulation of the E3 ubiquitin-protein ligase Nedd4.

Authors:  Younghee Ahn; Chae Young Hwang; Seung-Rock Lee; Ki-Sun Kwon; Cheolju Lee
Journal:  Biochem J       Date:  2008-06-01       Impact factor: 3.857

10.  Specific function of phosphoinositide 3-kinase beta in the control of DNA replication.

Authors:  Miriam Marqués; Amit Kumar; Ana M Poveda; Susana Zuluaga; Carmen Hernández; Shaun Jackson; Philippe Pasero; Ana C Carrera
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-22       Impact factor: 11.205

View more
  21 in total

1.  Suppression of survival signalling pathways by the phosphatase PHLPP.

Authors:  Audrey K O'Neill; Matthew J Niederst; Alexandra C Newton
Journal:  FEBS J       Date:  2012-03-16       Impact factor: 5.542

Review 2.  PTEN function: the long and the short of it.

Authors:  Benjamin D Hopkins; Cindy Hodakoski; Douglas Barrows; Sarah M Mense; Ramon E Parsons
Journal:  Trends Biochem Sci       Date:  2014-03-18       Impact factor: 13.807

3.  Ligand-independent activation of the P2X7 receptor by Hsp90 inhibition stimulates motor neuron apoptosis.

Authors:  Amy L Strayer; Cassandra N Dennys-Rivers; Karina C Ricart; Narae Bae; Joseph S Beckman; Maria Clara Franco; Alvaro G Estevez
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-29

4.  Chemoattractant concentration-dependent tuning of ERK signaling dynamics in migrating neutrophils.

Authors:  Elizabeth R Zhang; Shanshan Liu; Lani F Wu; Steven J Altschuler; Melanie H Cobb
Journal:  Sci Signal       Date:  2016-12-13       Impact factor: 8.192

5.  P2X7R antagonism after subfailure overstretch injury of blood vessels reverses vasomotor dysfunction and prevents apoptosis.

Authors:  Weifeng Luo; Daniel Feldman; Reid McCallister; Colleen Brophy; Joyce Cheung-Flynn
Journal:  Purinergic Signal       Date:  2017-09-13       Impact factor: 3.765

6.  PTEN lipid phosphatase activity and proper subcellular localization are necessary and sufficient for down-regulating AKT phosphorylation in the nucleus in Cowden syndrome.

Authors:  Xin He; Motoyasu Saji; Deepa Radhakrishnan; Todd Romigh; Joanne Ngeow; Qi Yu; Yu Wang; Matthew D Ringel; Charis Eng
Journal:  J Clin Endocrinol Metab       Date:  2012-09-07       Impact factor: 5.958

Review 7.  Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance.

Authors:  Elaine Xu; Michael Schwab; André Marette
Journal:  Rev Endocr Metab Disord       Date:  2014-03       Impact factor: 6.514

Review 8.  The emerging role of large immunophilin FK506 binding protein 51 in cancer.

Authors:  S Romano; A Sorrentino; A L Di Pace; G Nappo; C Mercogliano; M F Romano
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

9.  P2X7 Receptor Function in Bone-Related Cancer.

Authors:  Elena Adinolfi; Francesca Amoroso; Anna Lisa Giuliani
Journal:  J Osteoporos       Date:  2012-08-16

10.  P2X7 integrates PI3K/AKT and AMPK-PRAS40-mTOR signaling pathways to mediate tumor cell death.

Authors:  Shu Bian; Xiaofeng Sun; Aiping Bai; Chunqing Zhang; Linglin Li; Keiichi Enjyoji; Wolfgang G Junger; Simon C Robson; Yan Wu
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.